Integrative Physiology/Experimental Medicine Antiatherosclerotic Effect of an Antibody That Binds to Extracellular Matrix Glycosaminoglycans

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Global atlas on cardiovascular disease prevention and control.

  2011cited by this paper
• Switching on cytotoxicity by a single mutation at the heavy chain variable region of an anti-ganglioside antibody.

  2011cited by this paper
• Lipofundin-Induced Hyperlipidemia Promotes Oxidative Stress and Atherosclerotic Lesions in New Zealand White Rabbits

  2011cited by this paper
• Experimental immunotherapeutic approaches for atherosclerosis.

  2010cited by this paper
• Apolipoprotein E knock-out and knock-in mice: atherosclerosis, metabolic syndrome, and beyond This work was supported by National Institutes of Health Grant HL-042630. Published, JLR Papers in Press, December 5, 2008.

  2009cited by this paper
• Proteoglycan mediated lipoprotein retention: A mechanism of diabetic atherosclerosis

  2008cited by this paper
• Biosynthesis of Natural and Hyperelongated Chondroitin Sulfate Glycosaminoglycans: New Insights into an Elusive Process

  2008cited by this paper
• Characterization of the Antibody Response against NeuGcGM3 Ganglioside Elicited in Non-Small Cell Lung Cancer Patients Immunized with an Anti-Idiotype Antibody1

  2008cited by this paper
• 1E10 anti-idiotype vaccine in non-small cell lung cancer: Experience in stage IIIb/IV patients.

  2007cited by this paper
• Gangliosides, Ab1 and Ab2 antibodies I. Towards a molecular dissection of an idiotype-anti-idiotype system.

  2007cited by this paper
• Ira Tabas , Kevin Jon Williams and Jan Borén and Therapeutic Implications Subendothelial Lipoprotein Retention as the Initiating Process in Atherosclerosis : Update

  2007cited by this paper
• Apolipoprotein A-I/HDL infusion therapy for plaque stabilization-regression: a novel therapeutic approach.

  2007cited by this paper
• Vascular wall proteoglycan synthesis and structure as a target for the prevention of atherosclerosis

  2007cited by this paper
• Endostatin binds biglycan and LDL and interferes with LDL retention to the subendothelial matrix during atherosclerosiss⃞s⃞ The online version of this article (available at http://www.jlr.org) contains an additional figure Published, JLR Papers in Press, July 1, 2005. DOI 10.1194/jlr.M500241-JLR200

  2005cited by this paper
• Glutathione, Stress Responses, and Redox Signaling in Lung Inflammation

  2005cited by this paper
• Effect of pravastatin on malondialdehyde-modified low-density lipoprotein levels and coronary plaque regression as determined by three-dimensional intravascular ultrasound.

  2005cited by this paper
• Molecular Interactions Leading to Lipoprotein Retention and the Initiation of Atherosclerosis

  2004cited by this paper
• Role of oxidative modifications in atherosclerosis.

  2004cited by this paper
• Chimeric Anti-N-Glycolyl-Ganglioside and Its Anti-Idiotypic MAbs: Immunodominance of Their Variable Regions

  2003cited by this paper
• Immunoglobulin treatment suppresses atherosclerosis in apolipoprotein E-deficient mice via the Fc portion.

  2003cited by this paper
• AOPP-induced activation of human neutrophil and monocyte oxidative metabolism: a potential target for N-acetylcysteine treatment in dialysis patients.

  2003cited by this paper
• Inhibition of Atherosclerosis in ApoE-Null Mice by Immunization with ApoB-100 Peptide Sequences

  2003cited by this paper
• The safety and immunogenicity of a CETP vaccine in healthy adults.

  2003cited by this paper
• An Anti-Idiotype Vaccine Elicits a Specific Response to N-Glycolyl Sialic Acid Residues of Glycoconjugates in Melanoma Patients1

  2002cited by this paper
• Subendothelial retention of atherogenic lipoproteins in early atherosclerosis

  2002cited by this paper
• Interactions of lipoproteins with proteoglycans.

  2001cited by this paper
• Clinical significance of antibody against oxidized low density lipoprotein in patients with atherosclerotic coronary artery disease.

  2001cited by this paper
• [Why are plasmatic apoB lipoproteins atherogenic? The hypothesis of response to retention].

  2001cited by this paper
• Mechanisms of the pro- and anti-oxidant actions of nitric oxide in atherosclerosis.

  2000cited by this paper
• An animal model to study local oxidation of LDL and its biological effects in the arterial wall.

  1998cited by this paper
• Identification of the principal proteoglycan-binding site in LDL. A single-point mutation in apo-B100 severely affects proteoglycan interaction without affecting LDL receptor binding.

  1998cited by this paper
• Proteoglycans in macrophages: characterization and possible role in the cellular uptake of lipoproteins.

  1998cited by this paper
• Role of macrophage glycosaminoglycans in the cellular catabolism of oxidized LDL by macrophages.

  1998cited by this paper
• Syngeneic Anti-Idiotypic Monoclonal Antibodies to an Anti-NeuGc-Containing Ganglioside Monoclonal Antibody

  1998cited by this paper
• Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease.

  1998cited by this paper
• Endothelial constitutive nitric oxide synthase protein and mRNA increased in rabbit atherosclerotic aorta despite impaired endothelium-dependent vascular relaxation.

  1996cited by this paper
• Generation of a Murine Monoclonal Antibody Specific for N-Glycolylneuraminic Acid-Containing Gangliosides That Also Recognizes Sulfated Glycolipids

  1995cited by this paper
• The response-to-retention hypothesis of early atherogenesis.

  1995cited by this paper
• Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics.

  1995cited by this paper
• A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association.

  1995cited by this paper
• Effect of arterial proteoglycans and glycosaminoglycans on low density lipoprotein oxidation and its uptake by human macrophages and arterial smooth muscle cells.

  1992cited by this paper
• Aortic antioxidant defence mechanisms: time-related changes in cholesterol-fed rabbits.

  1990cited by this paper
• Influence of artificial fat emulsions on the composition of serum lipoproteins in humans.

  1986cited by this paper
• A new model for arteriosclerosis. An electron-microscopic study of the lesions induced by i.v. administered fat.

  1982cited by this paper
• Implications of the presence of an internal image of the antigen in anti-idiotypic antibodies: possible application to vaccine production.

  1981cited by this paper
• Towards a network theory of the immune system.

  1973cited by this paper

• Study on the Anti-Inflammatory Activity of Chondroitin Sulfate-Curcumin Amphiphilic Polymers

  2025cites this paper
• VSMCs in Atherosclerosis: Implications on the Role of Inflammation and Extracellular Matrix Remodelling.

  2025cites this paper
• Response to retention hypothesis as a source of targets for arterial wall-directed therapies to prevent atherosclerosis: A critical review.

  2024cites this paper
• Mechanisms modulating foam cell formation in the arterial intima: exploring new therapeutic opportunities in atherosclerosis

  2024cites this paper
• A bibliometric analysis of immunotherapy for atherosclerosis: trends and hotspots prediction

  2024cites this paper
• Characterization and Antiatherogenic Potential of P3R99 Monoclonal Antibody Against Sulfated Glycosaminoglycans: Physicochemical and Functional Insights

  2024influential citation
• Gua Lou Er Chen decoction attenuates atherosclerosis by reducing proteoglycans accumulation and inflammation.

  2023cites this paper
• The Greatly Under-Represented Role of Smooth Muscle Cells in Atherosclerosis

  2023cites this paper
• Smooth Muscle Cell—Macrophage Interactions Leading to Foam Cell Formation in Atherosclerosis: Location, Location, Location

  2022cites this paper
• Overfeeding Saturated Fat Increases LDL (Low-Density Lipoprotein) Aggregation Susceptibility While Overfeeding Unsaturated Fat Decreases Proteoglycan-Binding of Lipoproteins

  2021cites this paper
• Smooth Muscle Cell-Proteoglycan-Lipoprotein Interactions as Drivers of Atherosclerosis.

  2020cites this paper
• Interaction of arterial proteoglycans with low density lipoproteins (LDLs): From theory to promising therapeutic approaches

  2019cites this paper
• Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities

  2019cites this paper
• Signalling pathways regulating galactosaminoglycan synthesis and structure in vascular smooth muscle: Implications for lipoprotein binding and atherosclerosis

  2018influential citation
• A role for proteoglycans in vascular disease.

  2018cites this paper
• Atheroregressive Potential of the Treatment with a Chimeric Monoclonal Antibody against Sulfated Glycosaminoglycans on Pre-existing Lesions in Apolipoprotein E-Deficient Mice

  2017cites this paper
• Dose-Dependent Induction of an Idiotypic Cascade by Anti-Glycosaminoglycan Monoclonal Antibody in apoE−/− Mice: Association with Atheroprotection

  2017cites this paper
• Diagnosis and Treatment of Atherosclerosis: A Review Article

  2016cites this paper
• Arresting progressive atherosclerosis by immunization with an anti-glycosaminoglycan monoclonal antibody in apolipoprotein E-deficient mice.

  2015influential citation
• EL TRATAMIENTO CON EL ANTICUERPO MONOCLONAL CHP3R99 DISMINUYE LA INFILTRACIÓN DE MACRÓFAGOS EN LA ÍNTIMA ARTERIAL DE CONEJOS NZB.

  2015cites this paper
• EL TRATAMIENTO CON EL ANTICUERPO ANTI-PROTEOGLICANO CHP3R99 NO AFECTA LA BIOENERGÉTICA MITOCONDRIAL EN RATONES

  2015influential citation
• Targeting arterial wall sulfated glycosaminoglycans in rabbit atherosclerosis with a mouse/human chimeric antibody

  2014cites this paper
• Development and application of targeted therapeutic protein conjugates

  2014cites this paper
• Anti-idiotypic antibodies

  2014cites this paper
• Decorin and biglycan retain LDL in disease-prone valvular and aortic subendothelial intimal matrix.

  2014cites this paper
• The response-to-retention hypothesis: From theory to the potential therapeutic approaches

  2014cites this paper
• Biological functions of iduronic acid in chondroitin/dermatan sulfate

  2013cites this paper
• The treatment with an anti-glycosaminoglycan antibody reduces aortic oxidative stress in a rabbit model of atherosclerosis

  2013cites this paper
• New targets for glycosaminoglycans and glycosaminoglycans as novel targets

  2013cites this paper
• New Alternatives for Atherosclerosis Treatment Based on Immunomodulation

  2012cites this paper
• Inhibition of macrophage metabolism by oxLDL

  2012cites this paper
• LDL as a Cause of Atherosclerosis

  2012cites this paper
• Induction of Anti-Anti-Idiotype Antibodies Against Sulfated Glycosaminoglycans Reduces Atherosclerosis in Apolipoprotein E–Deficient Mice

  2012cites this paper
• Degree of Doctor ofin Biochemistry

  2012cites this paper